Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing product candidates to treat CNS diseases. Minerva’s goal is to transform the lives of patients with ...

Add Yahoo as a preferred source to see more of our stories on Google. On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.

In April 2025, CMG Pharmaceutical, a subsidiary of CHA Biotech, secured FDA approval for Mezofy (formerly Depipzo), an oral ...

Researchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, Technology and Research (A*STAR) have made strides in understanding the ...

On Thursday, the FDA approved Bristol Myers Squibb & Co’s (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology ...

The Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), making it the first major advancement in schizophrenia treatment in decades. Unlike existing medications that ...

Schizophrenia is a complex mental health disorder, but scientists are learning more about what can cause it... | Genetics And ...

This post was co-authored by Shontae Cameron, and Robert T. Muller, Ph.D. The World Health Organization estimates that schizophrenia affects around 24 million people, or roughly 1 in 300 individuals ...

Sexual dysfunction is a common side effect of antipsychotics, but it doesn’t have to be permanent. Learn about causes, switching meds, and restoring intimacy.

A new study has identified the brain connectivity patterns that lead to cognitive difficulties in patients with schizophrenia, suggesting potential targets for therapeutic intervention in early ...